


PHARMACEUTICAL 2022

Lyell Immunopharma Inc. Rank 138 of 466







PHARMACEUTICAL 2022

Lyell Immunopharma Inc. Rank 138 of 466



The relative strengths and weaknesses of Lyell Immunopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lyell Immunopharma Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 41% points. The greatest weakness of Lyell Immunopharma Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 42% points.

The company's Economic Capital Ratio, given in the ranking table, is 203%, being 126% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	626,286
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	46,738
Liabilities, Non-Current	150,881
Other Assets	381,022
Other Compr. Net Income	-1,879
Other Expenses	-2,324
Other Liabilities	0
Other Net Income	-35,443
Other Revenues	10,650
Property and Equipment	120,098
Research and Development	138,693
Selling, General and Administrative Expense	89,057

Output Variable	Value in 1000 USD
Assets	1,127,406
Liabilities	197,619
Expenses	225,426
Revenues	10,650
Stockholders Equity	929,787
Net Income	-250,219
Comprehensive Net Income	-251,158
Economic Capital Ratio	203%

